PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28028514-6 2016 RESULTS: After 1 month of melatonin treatment, the mean level of ICAM, VCAM, and CRP showed a statistically significant decrease in the case group. Melatonin 26-35 C-reactive protein Homo sapiens 81-84 34418903-6 2021 Clinical symptoms and C-reactive protein (CRP) were measured before and after treatment in the melatonin received and control (regular medications) groups. Melatonin 95-104 C-reactive protein Homo sapiens 22-40 34562971-10 2021 Recently, a randomized controlled study reported that low doses of melatonin significantly improved symptoms in hospitalized COVID-19 patients, leading to more rapid discharge with no side effects, while significantly decreasing levels of CRP, proinflammatory cytokines, and modulating dysregulated genes governing cellular and humoral immunity. Melatonin 67-76 C-reactive protein Homo sapiens 239-242 26644840-0 2015 Effect of topical application of melatonin on serum levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in patients with type 1 or type 2 diabetes and periodontal disease. Melatonin 33-42 C-reactive protein Homo sapiens 62-80 26644840-1 2015 BACKGROUND: The present clinical trial study was designed to assess the effect of topical application of melatonin on serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and C-reactive protein (CRP) in patients with diabetes and periodontal disease in comparison with healthy controls. Melatonin 105-114 C-reactive protein Homo sapiens 200-218 26644840-1 2015 BACKGROUND: The present clinical trial study was designed to assess the effect of topical application of melatonin on serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and C-reactive protein (CRP) in patients with diabetes and periodontal disease in comparison with healthy controls. Melatonin 105-114 C-reactive protein Homo sapiens 220-223 26644840-7 2015 Following topical melatonin application, there was a statistically significant decrease in the gingival index and pocket depth (P < 0.001) as well as a significant decrease in IL-6 and CRP serum levels (P < 0.001). Melatonin 18-27 C-reactive protein Homo sapiens 188-191 26644840-8 2015 Local melatonin application in patients with diabetes and periodontal disease resulted in a significant decrease in CRP and IL-6 serum levels as well as an improvement in the gingival index and pocket depth. Melatonin 6-15 C-reactive protein Homo sapiens 116-119 16377274-0 2006 Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Melatonin 22-31 C-reactive protein Homo sapiens 42-60 16377274-3 2006 However, little is known about the association between melatonin and C-reactive protein in patients with ischemic heart disease. Melatonin 55-64 C-reactive protein Homo sapiens 69-87 35581997-11 2022 Conclusion: High-dose melatonin in intubated patients with COVID-19 was associated with a decrease in CRP levels. Melatonin 22-31 C-reactive protein Homo sapiens 102-105 31790604-6 2020 Furthermore, MEL ingestion attenuated the hematologic parameters before and after exercise (White Blood Cells (WBC: p < .001 and p < .001, respectively); Neutrophiles (NE: p < .001 and p < .001, respectively); Lymphocytes (LY: p < .001 and p < .001, respectively)) and the ultra-sensitive C-reactive protein (us-CRP: p < .001 and p < .001; respectively) compared to PLA. Melatonin 13-16 C-reactive protein Homo sapiens 307-325 32951715-9 2020 CONCLUSIONS: Administration of 6 mg/day melatonin had improvement effect on many factors related to NAFLD such as liver enzymes, hs-CRP, anthropometric measurements, blood pressure, leptin serum levels and the grade of fatty liver. Melatonin 40-49 C-reactive protein Homo sapiens 132-135 32723264-3 2021 This study assessed the efficacy of sublingual consumption of melatonin in reducing necrosis and inflammation, in patients undergoing CABG with respect to C-reactive protein (hs-CRP), Creatine KinaseMuscle-Brain subunits (CK-MB) and cardiac Troponin T (cTnT) levels. Melatonin 62-71 C-reactive protein Homo sapiens 155-173 32723264-12 2021 CONCLUSION: Our findings suggest that the administration of melatonin may help modulate oxidative stress, based on the reduction of the levels of hs-CRP, CK-MB, and the duration of AF following CABG surgery. Melatonin 60-69 C-reactive protein Homo sapiens 149-152 31597622-7 2020 In addition, melatonin administration resulted in a significant reduction in serum high sensitivity C-reactive protein (beta = -1.92 mg/L, 95% CI -3.02 to -0.83, P = .001) and plasma malondialdehyde (beta = -0.21 mumol/L, 95% CI -0.36 to -0.06, P = .005); also, significant rises in plasma total antioxidant capacity (beta = 253.87 mmol/L, 95% CI 189.18-318.56, P < .001) and nitric oxide levels (beta = 2.99 mumol/L, 95% CI 0.71-5.28, P = .01) were observed compared with the placebo. Melatonin 13-22 C-reactive protein Homo sapiens 100-118 35220312-6 2022 RESULTS: After the intervention, the combination of propolis and melatonin significantly reduced interleukin-6 (-55.282 pg/ml ) and C-reactive protein (-21.656 mg/l ) levels, while increasing gavage intake (326.680 ml/day ) and improving some clinical outcomes (APACHE II, SOFA and NUTRIC scores) compared to control group. Melatonin 65-74 C-reactive protein Homo sapiens 132-150 31679041-9 2020 The effect of melatonin on CRP levels was marginal (WMD = - 0.45 mg/L; 95% CI - 0.94, 0.03; P = 0.06; I2 = 96.6%, Pheterogeneity < 0.001). Melatonin 14-23 C-reactive protein Homo sapiens 27-30 29949232-6 2019 Additionally, melatonin intake resulted in a significant reduction in serum high sensitivity C-reactive protein (beta -0.15; 95% CI, -0.27, -0.02; P = 0.02), malondialdehyde (beta -0.31; 95% CI, -0.57, -0.05; P = 0.02) and protein carbonyl (beta -0.06; 95% CI, -0.09, -0.04; P < 0.001). Melatonin 14-23 C-reactive protein Homo sapiens 93-111 31432072-8 2019 Analyses using KEGG-defined pathways revealed statistically significant differences in tryptophan metabolism between diets, with kynurenine and melatonin positively associated with serum C-reactive protein concentrations. Melatonin 144-153 C-reactive protein Homo sapiens 187-205 30012383-8 2018 Pooled analysis revealed statistically significant mean differences in CRP serum levels (mg/L) between groups at 24 h post-adjunctive therapy with melatonin (-1.739 mg/L; 95% CI: -3.205 to -0.273; P = 0.020). Melatonin 147-156 C-reactive protein Homo sapiens 71-74 29907916-8 2018 CONCLUSIONS: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-alpha levels among patients with MetS and related disorders. Melatonin 82-91 C-reactive protein Homo sapiens 119-122